Lupus drug anifrolumab tested as a simple shot
NCT ID NCT07688980
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This study tests anifrolumab, a drug for systemic lupus erythematosus (SLE), given either as a shot under the skin or through an IV. The goal is to see how the body processes the drug and check its safety. About 92 adults with lupus will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- anifrolumab
- What this could lead to
- If successful, this could lead to a more convenient way to give anifrolumab for lupus, potentially improving quality of life for patients.
- What could go wrong
- This is an early phase 1 trial with a small number of participants. The drug may not work as hoped, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smartphone app bridge the lupus care gap for women of color?
- Blood traps may reveal lupus kidney treatment success
- Can a peer coach help young people take control of their chronic illness?
- Lupus patients may get a boost from doctors checking their prescription refill records
- Engineered immune cells take aim at Hard-to-Treat autoimmune diseases
- New Four-Pronged antibody takes aim at lupus